{"nctId":"NCT00935818","briefTitle":"Varenicline and Bupropion for Smoking Cessation","startDateStruct":{"date":"2009-09"},"conditions":["Smoking"],"count":506,"armGroups":[{"label":"varenicline and buproprion SR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Varenicline","Drug: bupropion SR"]},{"label":"varenicline and placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Varenicline","Drug: placebo"]}],"interventions":[{"name":"Varenicline","otherNames":["chantix"]},{"name":"placebo","otherNames":["sugar pill"]},{"name":"bupropion SR","otherNames":["wellbutrin SR","zyban"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is at least 18 years of age;\n2. Subject has provide written informed consent;\n3. Subject is smoking greater than or equal to 10 cigarettes per day for at least 6 months;\n\n3\\) Subject is able to complete all study visits 4) Subject is in good health as determined by the investigator 5) Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments 6) Subject is motivated to stop smoking.\n\nExclusion Criteria:\n\nFemale and were pregnant, lactating or likely to become pregnant during the trial and not able nor willing to use contraception or had:\n\n1. an unstable medical condition;\n2. another household member participating in the study;\n3. bupropion or varenicline allergy;\n4. current use (previous 30 days) of a tobacco dependence treatment and unable or unwilling to discontinue use;\n5. an unstable medical condition or unstable angina, myocardial infarction, or coronary angioplasty (past 3 months) or an untreated cardiac dysrhythmia;\n6. a history of renal failure or were on renal dialysis;\n7. a history of seizures;\n8. as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts or lifetime history of a suicidal attempt (defined as \"potentially self-injurious act committed with at least some wish to die, as a result of act\");\n9. a history of closed head trauma associated with \\> 30 minutes of loss of consciousness, amnesia, skull fracture, subdural hematoma, or brain contusion;\n10. a history or psychosis, bipolar disorder, bulimia or anorexia nervosa;\n11. current moderate or severe depression as assessed by a score of â‰¥ 20 on the Beck Depression Inventory, Second Edition (BDI-II) 10;\n12. active substance abuse other than nicotine;\n13. current (past 14 days) use of an antipsychotic, monoamine oxidase inhibitors, or drugs known to interact with bupropion SR;\n14. a recent dose change of their antidepressant (within last 3 months);\n15. untreated hypertension or baseline systolic blood pressure \\> 180 or diastolic \\> 100;\n16. current treatment with another investigational drug for tobacco dependence (previous 30 days); or\n17. current use of bupropion or varenicline (previous 30 days).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers.","description":"Prolonged smoking abstinence is defined as no smoking, not even a puff, in the last 7 days, and a negative response to the question \"Since 2 weeks after your target quit date, have you smoked any tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks?\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Gain From Baseline to 3 Months","description":"Weight change from baseline to three months in those who met criteria for prolonged abstinence at the 3 month visit","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.4"},{"groupId":"OG001","value":"2.5","spread":"2.7"}]}]}]},{"type":"PRIMARY","title":"Point Prevalence Abstinence at 3 Months.","description":"biochemically confirmed 7-day point prevalence abstinence defined as no smoking, not even a puff, in the previous 7 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Point Prevalence Abstinence at 6 Months.","description":"Biochemically confirmed abstinence as no smoking, even a puff, for the prior 7 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Prolonged Abstinence at 12 Months","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Point Prevalence Abstinence at 12 Months","description":"Biochemically confirmed abstinence defined as no smoking, not even a puff, in the last 7 days","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":249},"commonTop":["sleep disturbance","nausea","constipation","headache","irritability"]}}}